Abstract
Intraperitoneal (IP) chemotherapy for advanced ovarian cancer improves both overall and disease-free survival. In this chapter, we compare the effectiveness of intravenous (IV) to IP chemotherapy. The evidence suggests an improvement in survival if some of the chemotherapy is administered via the IP route. The adverse events principally relate to the presence of a peritoneal catheter, including pain, catheter blockage, gastrointestinal effects, and infection.
A systematic search identified eight relevant randomized trials studying 1,819 women receiving primary treatment for ovarian cancer. Women were less likely to die if they received an IP component to the chemotherapy (hazard ratio = 0.80; 95% confidence interval [CI] = 0.71–0.90). Administering a component of chemotherapy by the IP route also prolongs the disease-free interval (0.79; 0.69–0.90) by almost 9 mo and increases complete response rates. There may, however, be greater pain, fever, and gastrointestinal toxicity, but less ototoxicity, using the IP route.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. The Cochrane Database of Systematic Reviews. 2006, Issue 1. Art. No.: CD005340. DOI: 10.1002/14651858.CD005340.pub2. Accessed February 20, 2007.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Available at: http://www.cochrane.org/resources/handbook/hbook.htm. Accessed February 20, 2007.
Zylberberg B, Ravina JH, Salat-Baroux J, et al. Polychimiotherapie des cancers de l’ovaire par voie mixte intraveineuse et intraperitoneale. Technique et resultats preliminaries. (Polychemotherapy of ovarian cancer via combined intravenous and intraperitoneal routes. Technique and preliminary results). Journal de gynecologie obstetrique et biologie de la reproduction 1986;15(5):671–676.
Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354(1):34–43.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815–2834.
Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19(4):1001–1007.
Kirmani S, Braly PS, McClay EF, et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 1994;54(3):338–344.
Gadducci A, Carnino F, Chiara S, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: A randomized trial of the Gruppo Oncologico Nord-Ovest SO. Gynecol Oncol 2000;76(2):157–162.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–1558.
Piccart MJ, Floquet A, Scarfone G, et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 2003;13(Suppl 2):196–203.
Polyzos A, Tsavaris N, Kosmas C, et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 1999;56(4):291–296.
Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335(26):1950–1955.
Yen MS, Juang CM, Lai CR, et al. Intraperitoneal cisplatin based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Intl J Gynecol Obstet 2001;72(1):55–60.
Wenzel LB, Huang H, Armstrong D, et al. Quality of life (QOL) results of a randomized study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial. J Clin Oncol 2004:22(14S):5026.
Massuger L, Jr., Verheijen R, Seiden M, et al. Intraperitoneal disease control after i.p. consolidation treatment with yttrium-90-labeled hmfg1 monoclonal antibody in patients with epithelial ovarian cancer. Gynecol Oncol 2005;96:909–1020.
Almadrones L, Yerys C. Problems associated with the administration of intraperitoneal therapy using the Port-a-cath system. Oncol Nurs Forum 1990;17(1);75–80.
Fujiwara K, Markman M, Morgan M, et al. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol 2005;97:10–15.
Makhija S, Leitao M, Sabbatini P, et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol 2001;81(1):77–81.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Jaaback, K. (2007). A Systematic Review and Meta-Analysis of Randomized Trials. In: Helm, C.W., Edwards, R.P. (eds) Intraperitoneal Cancer Therapy. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-195-6_3
Download citation
DOI: https://doi.org/10.1007/978-1-59745-195-6_3
Publisher Name: Humana Press
Print ISBN: 978-1-58829-878-2
Online ISBN: 978-1-59745-195-6
eBook Packages: MedicineMedicine (R0)